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primary one does not? Consideration of these questions 
will no doubt be useful in planning of the next trial.
In conclusion, Freeman and colleagues’ new-wave, 
high-quality, feasibility trial fully deserves a deﬁ nitive 
randomised controlled trial and, like all good science, 
raises as many questions as it answers.
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Improved identiﬁ cation of people at risk of psychosis: is it 
value for money?
Development of a psychotic illness, including schizo-
phrenia, can be debilitating for the individual, with life 
expectancy reduced by up to 15 years,1 mainly due to an 
increased occurrence of cardiovascular disease.2 In the 
past 5 years, clinician preference has moved towards 
early detection and intervention by assessment of 
the risks for developing psychoses, with increasing 
evidence about the eﬀ ectiveness of early interventions 
for psychosis.3 Primary care can play an important part 
in the early identiﬁ cation of individuals at risk, because 
people with a serious mental illness have an estimated 
average 13–14 consultations with their general 
practitioner every year.4 However, evidence is scarce 
with respect to the assessment of factors contributing 
to the eﬀ ectiveness of improved detection of individuals 
at high risk of developing psychosis in primary care. 
Additionally, in an era of restricted health-care 
budgets, the assessment of cost-eﬀ ectiveness for this 
type of intervention is important. Cost-eﬀ ectiveness 
assessments attempt to quantify the trade-oﬀ  between 
improved outcomes for the individual and increased 
costs to the health-care system; in other words, does the 
intervention represent value for money? 
In The Lancet Psychiatry, Jesus Perez and colleagues5 
report both the clinical eﬀ ectiveness and cost-eﬀ ective-
ness of a theory-based early intervention to improve 
liaison between primary and secondary care in UK 
primary care practices. High-intensity and low-intensity 
liaisons were assessed (26 practices in high-intensity 
intervention and 28 in low-intensity intervention), as 
was practice as usual (50 practices). The authors5 report 
that practices randomly assigned to the high-intensity 
intervention referred more individuals for ﬁ rst-episode 
psychosis to the early intervention services than did 
the other two practice groups (high intensity vs low 
intensity; incidence rate ratio [IRR] 1·9, 95% CI 1·05–3·4, 
p=0·04), although for individuals at high risk of 
psychosis the increase was not  signiﬁ cant. As a result, 
high-intensity practices referred both more true-
positive and false-positive cases of psychosis conﬁ rmed 
after assessment.
The increased referral of individuals at high risk of 
psychosis suggests that the high-intensity intervention 
is clinically eﬀ ective, but what about its cost-
eﬀ ectiveness? Implementation of the high-intensity 
liaison intervention was estimated to cost £1459 per 
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practice (low-intensity intervention cost was £14). 
However, results of the authors’ economic evaluation5 
suggest that this intervention would pay for itself (be 
cost-saving), with the total costs per true-positive 
referral being lowest in the high-intensity practices. 
Two key drivers are behind these cost-savings: a 
reduction in the number of late presenters (individuals 
whose psychosis is not identiﬁ ed early and are costly to 
treat) and a reduction in the costs of treating individuals 
at high risk who are treated early.
This study also emphasises5 both the importance 
of health-economic evaluations in psychiatry and the 
diﬃ  culties that can be encountered.
Heath-economic evidence can be used to make 
comparisons in diﬀ erent interventions, such as what 
oﬀ ers more value for money; the high intensity 
intervention described by Perez and colleagues,5 or a 
cancer drug? These comparisons can in turn be used to 
inform re-imbursement or commissioning decisions, 
but a standardised health outcome that can be used 
to make comparisons is needed. In some countries, a 
measure of health-related quality of life (HRQoL) can be 
used.6 However, assessment of the HRQoL of individuals 
with psychosis, and the eﬀ ect of interventions on this 
factor, is challenging and needs further research.7 It will 
be useful to see this type of patient-reported outcome 
measure included in future trials.
Perez and colleagues5 also show the important role of 
health-economic modelling. It is used in their study to 
include evidence not collected during their trial—notably 
the development of psychosis in patients at high risk 
who are not identiﬁ ed and the later costs of treating 
them. This ability to synthesise a range of evidence 
sources is a particular strength of health-economic 
models. Such models have also been used to map out 
care pathways (eg, for patients with depression8) and 
assess the potential eﬀ ect of any service changes on 
both patient outcomes and costs to the health-care 
system. Perez and colleagues5 have shown the cost-
eﬀ ectiveness of improved liaison between primary 
and secondary care. The next question to ask is how 
best to integrate this intervention into the broader 
care pathway of patients with, or at risk of, psychosis—
including pharmacotherapy, psychotherapy, and any 
follow-up checks (usually by general practioners, but 
can also be by secondary care services). Such a question 
would need an ambitious research project, with 
questions about cost-eﬀ ectiveness being a key aspect, 
along with questions about clinical eﬀ ectiveness and 
patient involvement to identify the main diﬃ  culties. 
However, these are the types of questions that should 
be asked to ensure that future research has the best 
possible eﬀ ect on patient health and the organisation 
and delivery of health services. 
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 Cooling suicide hotspots
The results of the meta-analysis by Jane Pirkis and 
colleagues1 again underscore that restricting access 
to methods of suicide saves lives.2 They showed that 
inhibiting access greatly reduced suicide rates at 
suicide hotspots, and that promoting help-seeking 
or third party intervention also seemed to oﬀ er 
protection for those who seek to end their lives at 
these sites. When examined in a tight focus that 
looks exclusively at these settings, suicides are clearly 
preventable. 
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